Latest Growth factor Stories
Massachusetts General Hospital (MGH) researchers have discovered the first of an entirely new class of antiangiogenesis drugs â€“ agents that interfere with the development of blood vessels.
Scientists identify in the journal Nature a new molecular pathway used to suppress blood vessel branching in the developing retina â€“ a finding with potential therapeutic value for fighting diseases of the retina and a variety of cancers.
Muscular-skeleton, joint injuries and arthritis affect over 100 million Americans, or one in every three people. A majority of these people develop chronic problems and disability.
Cancer has a mighty big bag of tricks that it uses to evade the body's natural defense mechanisms and proliferate.
A low cost, nanometer-sized drug to treat chronic wounds, such as diabetic foot ulcers or burns, has been developed by a group of scientists from the Hebrew University of Jerusalem, Harvard Medical School and others in the U.S. and Japan.
PALO ALTO, Calif., Oct. 26 /PRNewswire/ -- Telik, Inc.
A new study describes how a carbohydrate-binding protein, galectin-3, promotes angiogenesis, the growth of new blood vessels.
Dr. Jean-Philippe Gratton, Director of the Endothelial cell biology research unit at the Institut de recherches cliniques de MontrÃ©al (IRCM), identifies a new intracellular mechanism responsible for modulating vascular permeability: the nitrosylation of beta-catenin protein by nitric oxide.
Implanting tiny plastic scaffolds seeded with genetically engineered stem cells reduced organ damage and led to better cardiac function after a heart attack.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.